Mammographic and contrast-enhanced spectral mammography imaging findings of HER2-positive cancers according to hormone receptor status

Abstract Background Breast cancer is the leading cause of cancer-related mortality in women. Human epidermal growth factor receptor 2 (HER2) overexpression seen 20 out 100 invasive breast cancers. Among HER2+ patients, two distinct hormone (HR) subtypes can be defined: HR-positive (HR+) and HR-negative (HR−) each which with unique therapeutic response survival pattern. Contrast-enhanced spectral mammography (CESM) an emerging novel imaging modality that offers diagnostic performance comparable to contrast-enhanced MRI. The purpose this retrospective study was describe CESM features cancers according status assess whether specific mammographic differentiate between HER2+/HR+ HER2+/HR− potentially aiding treatment planning patients. Results A total 61 patients were included. Twenty-nine cases (47.5%) 32 (52.5%) HER2+/HR−. No statistically significant difference found presentations hormonal status. HR- more likely multifocal ( P 0.018), rounded or oval (P 0.008), circumscribed 0.004), associated non-mass enhancement (NME) < 0.001). HR+ showed a tendency for irregular shape spiculated outline heterogeneous 0.021) ring 0.046) enhancement. Conclusions tumors have different demographic, pathologic Because HER2 clinical outcomes, enhance patient outcome by accelerating diagnosis treatment.